Qiang Liu
Founder at Tangent Capital, Inc.
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Bai Zhong Xue | M | 59 |
China Nuokang Bio-Pharmaceutical, Inc.
China Nuokang Bio-Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology China Nuokang Bio-Pharmaceutical, Inc. is a biopharmaceutical company focused on the research, development, manufacture, marketing and sales of hematological and cardiovascular products. It currently sells a portfolio of fourteen products, including three principal products: Baquting, its flagship bleeding control product; Aiduo, its cardiovascular stress imaging agent; and Aiwen, its anti-arrhythmic agent. The company has also entered into an exclusive agreement for the marketing and distribution in China of Kaitong, an intravenous injectable lipid emulsion of vasodilator alprostadil for the treatment of peripheral vascular diseases, cardiocerebral microcirculation disorders and post-surgery thrombosis. Its product pipeline includes four product candidates under development that address the growing market and medical needs for hematological, cardiovascular and cerebrovascular disease diagnosis, treatment and prevention. The company was founded on November 1997 and is headquartered in Shenyang, China. | 27 years |
Xiao Ying Gao | M | 74 |
China Nuokang Bio-Pharmaceutical, Inc.
China Nuokang Bio-Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology China Nuokang Bio-Pharmaceutical, Inc. is a biopharmaceutical company focused on the research, development, manufacture, marketing and sales of hematological and cardiovascular products. It currently sells a portfolio of fourteen products, including three principal products: Baquting, its flagship bleeding control product; Aiduo, its cardiovascular stress imaging agent; and Aiwen, its anti-arrhythmic agent. The company has also entered into an exclusive agreement for the marketing and distribution in China of Kaitong, an intravenous injectable lipid emulsion of vasodilator alprostadil for the treatment of peripheral vascular diseases, cardiocerebral microcirculation disorders and post-surgery thrombosis. Its product pipeline includes four product candidates under development that address the growing market and medical needs for hematological, cardiovascular and cerebrovascular disease diagnosis, treatment and prevention. The company was founded on November 1997 and is headquartered in Shenyang, China. | 13 years |
Sean Shao | M | 67 |
China Nuokang Bio-Pharmaceutical, Inc.
China Nuokang Bio-Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology China Nuokang Bio-Pharmaceutical, Inc. is a biopharmaceutical company focused on the research, development, manufacture, marketing and sales of hematological and cardiovascular products. It currently sells a portfolio of fourteen products, including three principal products: Baquting, its flagship bleeding control product; Aiduo, its cardiovascular stress imaging agent; and Aiwen, its anti-arrhythmic agent. The company has also entered into an exclusive agreement for the marketing and distribution in China of Kaitong, an intravenous injectable lipid emulsion of vasodilator alprostadil for the treatment of peripheral vascular diseases, cardiocerebral microcirculation disorders and post-surgery thrombosis. Its product pipeline includes four product candidates under development that address the growing market and medical needs for hematological, cardiovascular and cerebrovascular disease diagnosis, treatment and prevention. The company was founded on November 1997 and is headquartered in Shenyang, China. | 16 years |
Shizheng Duan | M | 56 |
China Nuokang Bio-Pharmaceutical, Inc.
China Nuokang Bio-Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology China Nuokang Bio-Pharmaceutical, Inc. is a biopharmaceutical company focused on the research, development, manufacture, marketing and sales of hematological and cardiovascular products. It currently sells a portfolio of fourteen products, including three principal products: Baquting, its flagship bleeding control product; Aiduo, its cardiovascular stress imaging agent; and Aiwen, its anti-arrhythmic agent. The company has also entered into an exclusive agreement for the marketing and distribution in China of Kaitong, an intravenous injectable lipid emulsion of vasodilator alprostadil for the treatment of peripheral vascular diseases, cardiocerebral microcirculation disorders and post-surgery thrombosis. Its product pipeline includes four product candidates under development that address the growing market and medical needs for hematological, cardiovascular and cerebrovascular disease diagnosis, treatment and prevention. The company was founded on November 1997 and is headquartered in Shenyang, China. | 20 years |
Huining Cao | M | 58 |
China Nuokang Bio-Pharmaceutical, Inc.
China Nuokang Bio-Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology China Nuokang Bio-Pharmaceutical, Inc. is a biopharmaceutical company focused on the research, development, manufacture, marketing and sales of hematological and cardiovascular products. It currently sells a portfolio of fourteen products, including three principal products: Baquting, its flagship bleeding control product; Aiduo, its cardiovascular stress imaging agent; and Aiwen, its anti-arrhythmic agent. The company has also entered into an exclusive agreement for the marketing and distribution in China of Kaitong, an intravenous injectable lipid emulsion of vasodilator alprostadil for the treatment of peripheral vascular diseases, cardiocerebral microcirculation disorders and post-surgery thrombosis. Its product pipeline includes four product candidates under development that address the growing market and medical needs for hematological, cardiovascular and cerebrovascular disease diagnosis, treatment and prevention. The company was founded on November 1997 and is headquartered in Shenyang, China. | 14 years |
Felix Chungfai Wong | M | - |
China Nuokang Bio-Pharmaceutical, Inc.
China Nuokang Bio-Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology China Nuokang Bio-Pharmaceutical, Inc. is a biopharmaceutical company focused on the research, development, manufacture, marketing and sales of hematological and cardiovascular products. It currently sells a portfolio of fourteen products, including three principal products: Baquting, its flagship bleeding control product; Aiduo, its cardiovascular stress imaging agent; and Aiwen, its anti-arrhythmic agent. The company has also entered into an exclusive agreement for the marketing and distribution in China of Kaitong, an intravenous injectable lipid emulsion of vasodilator alprostadil for the treatment of peripheral vascular diseases, cardiocerebral microcirculation disorders and post-surgery thrombosis. Its product pipeline includes four product candidates under development that address the growing market and medical needs for hematological, cardiovascular and cerebrovascular disease diagnosis, treatment and prevention. The company was founded on November 1997 and is headquartered in Shenyang, China. | 12 years |
Hongying Wang | F | 51 |
China Nuokang Bio-Pharmaceutical, Inc.
China Nuokang Bio-Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology China Nuokang Bio-Pharmaceutical, Inc. is a biopharmaceutical company focused on the research, development, manufacture, marketing and sales of hematological and cardiovascular products. It currently sells a portfolio of fourteen products, including three principal products: Baquting, its flagship bleeding control product; Aiduo, its cardiovascular stress imaging agent; and Aiwen, its anti-arrhythmic agent. The company has also entered into an exclusive agreement for the marketing and distribution in China of Kaitong, an intravenous injectable lipid emulsion of vasodilator alprostadil for the treatment of peripheral vascular diseases, cardiocerebral microcirculation disorders and post-surgery thrombosis. Its product pipeline includes four product candidates under development that address the growing market and medical needs for hematological, cardiovascular and cerebrovascular disease diagnosis, treatment and prevention. The company was founded on November 1997 and is headquartered in Shenyang, China. | 26 years |
Kaijun Li | M | 54 |
China Nuokang Bio-Pharmaceutical, Inc.
China Nuokang Bio-Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology China Nuokang Bio-Pharmaceutical, Inc. is a biopharmaceutical company focused on the research, development, manufacture, marketing and sales of hematological and cardiovascular products. It currently sells a portfolio of fourteen products, including three principal products: Baquting, its flagship bleeding control product; Aiduo, its cardiovascular stress imaging agent; and Aiwen, its anti-arrhythmic agent. The company has also entered into an exclusive agreement for the marketing and distribution in China of Kaitong, an intravenous injectable lipid emulsion of vasodilator alprostadil for the treatment of peripheral vascular diseases, cardiocerebral microcirculation disorders and post-surgery thrombosis. Its product pipeline includes four product candidates under development that address the growing market and medical needs for hematological, cardiovascular and cerebrovascular disease diagnosis, treatment and prevention. The company was founded on November 1997 and is headquartered in Shenyang, China. | 17 years |
Yong Xu | M | 59 |
China Nuokang Bio-Pharmaceutical, Inc.
China Nuokang Bio-Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology China Nuokang Bio-Pharmaceutical, Inc. is a biopharmaceutical company focused on the research, development, manufacture, marketing and sales of hematological and cardiovascular products. It currently sells a portfolio of fourteen products, including three principal products: Baquting, its flagship bleeding control product; Aiduo, its cardiovascular stress imaging agent; and Aiwen, its anti-arrhythmic agent. The company has also entered into an exclusive agreement for the marketing and distribution in China of Kaitong, an intravenous injectable lipid emulsion of vasodilator alprostadil for the treatment of peripheral vascular diseases, cardiocerebral microcirculation disorders and post-surgery thrombosis. Its product pipeline includes four product candidates under development that address the growing market and medical needs for hematological, cardiovascular and cerebrovascular disease diagnosis, treatment and prevention. The company was founded on November 1997 and is headquartered in Shenyang, China. | 18 years |
Yan Xue | F | 47 |
China Nuokang Bio-Pharmaceutical, Inc.
China Nuokang Bio-Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology China Nuokang Bio-Pharmaceutical, Inc. is a biopharmaceutical company focused on the research, development, manufacture, marketing and sales of hematological and cardiovascular products. It currently sells a portfolio of fourteen products, including three principal products: Baquting, its flagship bleeding control product; Aiduo, its cardiovascular stress imaging agent; and Aiwen, its anti-arrhythmic agent. The company has also entered into an exclusive agreement for the marketing and distribution in China of Kaitong, an intravenous injectable lipid emulsion of vasodilator alprostadil for the treatment of peripheral vascular diseases, cardiocerebral microcirculation disorders and post-surgery thrombosis. Its product pipeline includes four product candidates under development that address the growing market and medical needs for hematological, cardiovascular and cerebrovascular disease diagnosis, treatment and prevention. The company was founded on November 1997 and is headquartered in Shenyang, China. | 22 years |
Jiuxiang Li | M | 53 |
China Nuokang Bio-Pharmaceutical, Inc.
China Nuokang Bio-Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology China Nuokang Bio-Pharmaceutical, Inc. is a biopharmaceutical company focused on the research, development, manufacture, marketing and sales of hematological and cardiovascular products. It currently sells a portfolio of fourteen products, including three principal products: Baquting, its flagship bleeding control product; Aiduo, its cardiovascular stress imaging agent; and Aiwen, its anti-arrhythmic agent. The company has also entered into an exclusive agreement for the marketing and distribution in China of Kaitong, an intravenous injectable lipid emulsion of vasodilator alprostadil for the treatment of peripheral vascular diseases, cardiocerebral microcirculation disorders and post-surgery thrombosis. Its product pipeline includes four product candidates under development that address the growing market and medical needs for hematological, cardiovascular and cerebrovascular disease diagnosis, treatment and prevention. The company was founded on November 1997 and is headquartered in Shenyang, China. | 20 years |
Tong Le | M | - |
China Nuokang Bio-Pharmaceutical, Inc.
China Nuokang Bio-Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology China Nuokang Bio-Pharmaceutical, Inc. is a biopharmaceutical company focused on the research, development, manufacture, marketing and sales of hematological and cardiovascular products. It currently sells a portfolio of fourteen products, including three principal products: Baquting, its flagship bleeding control product; Aiduo, its cardiovascular stress imaging agent; and Aiwen, its anti-arrhythmic agent. The company has also entered into an exclusive agreement for the marketing and distribution in China of Kaitong, an intravenous injectable lipid emulsion of vasodilator alprostadil for the treatment of peripheral vascular diseases, cardiocerebral microcirculation disorders and post-surgery thrombosis. Its product pipeline includes four product candidates under development that address the growing market and medical needs for hematological, cardiovascular and cerebrovascular disease diagnosis, treatment and prevention. The company was founded on November 1997 and is headquartered in Shenyang, China. | 12 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Yu Bin Yang | M | 50 |
The University of New South Wales
| 6 years |
Brad kim | M | - |
The University of New South Wales
| 4 years |
Yi Xin Huang | M | 57 |
The University of New South Wales
| 1 years |
Li Xin Niu | F | 52 |
China Nuokang Bio-Pharmaceutical, Inc.
China Nuokang Bio-Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology China Nuokang Bio-Pharmaceutical, Inc. is a biopharmaceutical company focused on the research, development, manufacture, marketing and sales of hematological and cardiovascular products. It currently sells a portfolio of fourteen products, including three principal products: Baquting, its flagship bleeding control product; Aiduo, its cardiovascular stress imaging agent; and Aiwen, its anti-arrhythmic agent. The company has also entered into an exclusive agreement for the marketing and distribution in China of Kaitong, an intravenous injectable lipid emulsion of vasodilator alprostadil for the treatment of peripheral vascular diseases, cardiocerebral microcirculation disorders and post-surgery thrombosis. Its product pipeline includes four product candidates under development that address the growing market and medical needs for hematological, cardiovascular and cerebrovascular disease diagnosis, treatment and prevention. The company was founded on November 1997 and is headquartered in Shenyang, China. | 6 years |
Mark Compton | M | 63 |
The University of New South Wales
| - |
GRANT Chen | M | 60 |
Jilin University
| 6 years |
Jiuann Haur Wong | M | 48 |
The University of New South Wales
| 5 years |
Eytan Uliel | M | - |
The University of New South Wales
| 7 years |
Ming De Yu | M | 78 |
China Nuokang Bio-Pharmaceutical, Inc.
China Nuokang Bio-Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology China Nuokang Bio-Pharmaceutical, Inc. is a biopharmaceutical company focused on the research, development, manufacture, marketing and sales of hematological and cardiovascular products. It currently sells a portfolio of fourteen products, including three principal products: Baquting, its flagship bleeding control product; Aiduo, its cardiovascular stress imaging agent; and Aiwen, its anti-arrhythmic agent. The company has also entered into an exclusive agreement for the marketing and distribution in China of Kaitong, an intravenous injectable lipid emulsion of vasodilator alprostadil for the treatment of peripheral vascular diseases, cardiocerebral microcirculation disorders and post-surgery thrombosis. Its product pipeline includes four product candidates under development that address the growing market and medical needs for hematological, cardiovascular and cerebrovascular disease diagnosis, treatment and prevention. The company was founded on November 1997 and is headquartered in Shenyang, China. | 5 years |
Kenneth John Fowlie | M | 56 |
The University of New South Wales
| 4 years |
Ho Yin Leung | M | 46 |
The University of New South Wales
| 6 years |
Alexander Mak | M | 55 |
The University of New South Wales
| 4 years |
Jonathan Lee Popper | M | - |
York University
| 7 years |
Darren Smorgon | M | - |
The University of New South Wales
| 4 years |
Qian Liu | F | 59 |
Jilin University
| 6 years |
William Keller | M | 75 |
China Nuokang Bio-Pharmaceutical, Inc.
China Nuokang Bio-Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology China Nuokang Bio-Pharmaceutical, Inc. is a biopharmaceutical company focused on the research, development, manufacture, marketing and sales of hematological and cardiovascular products. It currently sells a portfolio of fourteen products, including three principal products: Baquting, its flagship bleeding control product; Aiduo, its cardiovascular stress imaging agent; and Aiwen, its anti-arrhythmic agent. The company has also entered into an exclusive agreement for the marketing and distribution in China of Kaitong, an intravenous injectable lipid emulsion of vasodilator alprostadil for the treatment of peripheral vascular diseases, cardiocerebral microcirculation disorders and post-surgery thrombosis. Its product pipeline includes four product candidates under development that address the growing market and medical needs for hematological, cardiovascular and cerebrovascular disease diagnosis, treatment and prevention. The company was founded on November 1997 and is headquartered in Shenyang, China. | 3 years |
Jing Jia Ji | M | 69 |
The University of New South Wales
| 3 years |
Wen Yi Huang | M | 53 |
Jilin University
| 7 years |
Donglin Song | M | 67 |
Jilin University
| 7 years |
Natasha Morris | F | - |
The University of New South Wales
| 21 years |
Lirong Han | M | 61 |
Jilin University
| 6 years |
Syed Mujeeb Jafferi | M | 41 |
York University
| 4 years |
Sachit Kanwar | M | 42 |
York University
| 4 years |
Chi Kin Leung | M | 45 |
York University
| 4 years |
OMAR MORSON | M | - |
York University
| 5 years |
Wen Jie Zhou | M | 57 |
The University of New South Wales
| 4 years |
Marisa Jones | F | - |
York University
| 2 years |
Man Shing Chi | M | 60 |
The University of New South Wales
| 1 years |
Dan Cooper | M | - |
York University
| 3 years |
Shay Nulman | M | - |
York University
| 4 years |
Milena Glauberzon | F | - |
York University
| 4 years |
James Kevin Stimpson | M | - |
The University of New South Wales
| 4 years |
Diana Escobar Bold | F | - |
York University
| 3 years |
Duncan William Anderson | M | - |
York University
| 4 years |
Man Wai Si Tou | F | 47 |
The University of New South Wales
| 4 years |
William Bradley | M | 58 |
York University
| 4 years |
Kenneth Low | M | - |
York University
| 4 years |
Antonio Luciano Ciero | M | - |
York University
| 5 years |
Jane Kelly | F | - |
The University of New South Wales
| 4 years |
Jordan Lee Zinberg | M | 47 |
York University
| 4 years |
Hoi Kuen Chan | M | 40 |
The University of New South Wales
| 4 years |
Cheng Tun Teoh | M | 49 |
The University of New South Wales
| 4 years |
Sheetal Jaitly | M | 43 |
York University
| 4 years |
Steve Greenfield | M | - |
York University
| 4 years |
Pui Man Leung | F | 50 |
York University
| 4 years |
Alex Flesias | M | 49 |
York University
| 1 years |
Daniel Davidzon | M | - |
York University
| 8 years |
Edwin S. Chan | M | - |
York University
| 2 years |
JoAnne Halpern | F | - |
York University
| 2 years |
Kok Boon Woo | M | 46 |
York University
| 4 years |
Helen Rattee | F | - |
York University
| 2 years |
Thomas Stenvoll | M | - |
York University
| 4 years |
Robert Montesano | M | - |
York University
| 4 years |
Yuanita Rohali | F | 57 |
The University of New South Wales
| 1 years |
Kam Fai Edwin Chan | M | 58 |
York University
| 2 years |
John Markell | M | - |
York University
| 2 years |
Paul Fornazzari | M | 57 |
York University
| 3 years |
Anthony Francis Visano | M | - |
York University
| 5 years |
Sheel Parekh | M | - |
York University
| 2 years |
Sasha Cucuz | M | 46 |
York University
| 4 years |
Kai Wang | M | - |
York University
| 3 years |
Maxime Ménard | M | 49 |
York University
| 3 years |
Mark Knapp | M | - |
York University
| 2 years |
Jeffrey Woolley | M | - |
York University
| 2 years |
Allison M. Mendes | F | - |
York University
| 2 years |
Andrew M. Kuske | M | - |
York University
| 3 years |
Paul Steep | M | - |
York University
| 1 years |
Derrick Abraham | M | - |
York University
| 4 years |
Anthony C. Paniccia | M | - |
York University
| 4 years |
Rong Ni Qi | F | 45 |
York University
| 4 years |
Sze Wai Tso | M | 54 |
The University of New South Wales
| 4 years |
Chung Fai Pang | M | 51 |
The University of New South Wales
| 3 years |
Steven Hall | M | - |
York University
| 2 years |
Amelia See Man Tsang | F | - |
York University
| 4 years |
Walied Soliman | M | - |
York University
| 3 years |
Daniel Lee | M | - |
York University
| 4 years |
Andy Ko | M | - |
York University
| 4 years |
Jie Du | M | 69 |
Jilin University
| 1 years |
Matthew Winton | M | 46 |
York University
| 4 years |
Cameron J. C. Judson | M | - |
The University of New South Wales
| 4 years |
Anthony Pitirri | M | - |
York University
| 4 years |
Derek Teevan | M | - |
York University
| 1 years |
Goshen Benzaquen | M | - |
York University
| 4 years |
Richard H. Krempulec | M | - |
York University
| 3 years |
Slawek Kajko | M | 45 |
York University
| 4 years |
Jingdong Liu | M | 46 |
York University
| 4 years |
Stephen Matyasfalvi | M | - |
York University
| 2 years |
Ivana rezo | F | - |
York University
| 6 years |
Statistics
Country | Connections | % of total |
---|---|---|
Canada | 56 | 56.00% |
Australia | 23 | 23.00% |
China | 21 | 21.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Qiang Liu
- Personal Network